Pulmatrix Q3 2023 net loss $3.8M; cash $21.3M, runway into Q1 2025

Pulmatrix, Inc.

2023-Q3 EPS reported -$3.30 vs consensus -$1.07 ▼ miss (-208.1%)

Revenue $1.8M (-$0.1M YoY); net loss $3.8M ($1.03/share) vs $5.1M loss in prior year.
Cash $21.3M, down from $35.6M at Dec 2022; projected runway into Q1 2025.
PUR1900 Phase 2b in ABPA ongoing; topline data expected H2 2024.
PUR3100 IND cleared for Phase 2 in acute migraine; study start contingent on financing.
PUR1800 Phase 1b completed; seeking partnership for Phase 2.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Pulmatrix, Inc. reported the third fiscal quarter ended September 30, 2023 results: revenue $1.8 million.

Period: the third fiscal quarter ended September 30, 2023
Revenue: $1.8 million
Result: reported results

Exact text from the filing

plans to pursue partnership opportunities to advance PUR1800 into a potential Phase 2 clinical trial. Third Quarter 2023 Financial Results Revenues decreased $0.1 million to $1.8 million for the three months ended September 30, 2023 compared to $1.9 million for the three months ended September 30, 2022. The decrease is related to the Company’s revenues recognized

View on SEC.gov

Browse all earnings releases →

Pulmatrix, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-040009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.